Research
Hormonal
Daily supplementation with 300 mg of Palmitoylethanolamide (PEA) combined with 8 weeks of resistance training does not improve upper-body maximal strength (1-RM bench press) compared to placebo.
Do not take PEA expecting to get stronger. The study found that people taking the placebo actually got slightly stronger in their bench press than those taking PEA. PEA is useful for pain and power, but not for maximal strength.
GoodRefutesHIGH confidence
The PLA group had higher 1‑RM bench press post‑intervention compared with the PEA group (ITT: 2.24 kg [0.12, 4.37] p = 0.039; PP: 2.73 kg [0.40, 5.06] p = 0.023).
Why this rating
Double-blind RCT with statistically significant difference favoring placebo.
Source
The Effect of Palmitoylethanolamide (PEA) on Skeletal Muscle Hypertrophy, Strength, and Power in Response to Resistance Training in Healthy Active Adults: A Double-Blind Randomized Control Trial
Zoya Huschtscha et al. · Sports Medicine - Open · 2024
DOI 10.1186/s40798-024-00732-6
rct · n=52Cited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Daily supplementation with 300 mg of Palmitoylethanolamide (PEA) combined with 8 weeks of resistance training does not impair skeletal muscle hypertrophy gains compared to placebo.Good
- Daily supplementation with 300 mg of Palmitoylethanolamide (PEA) combined with 8 weeks of resistance training significantly improves lower-body dynamic power (jump height) compared to placebo.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →